Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses

Overview

Journal Pharmacoeconomics

Specialty Pharmacology

Date 2024 Aug 7

PMID 39110388

Authors

Ewan M Tomeny

Thomas Hampton

Phuong Bich Tran

Laura Rosu

Mphatso D Phiri

Kathryn A Haigh

Jasper Nidoi

Tom Wingfield

Eve Worrall

Affiliations

Soon will be listed here.

Abstract

Background: The disability-adjusted life year (DALY), a key metric for health resource allocation, encompasses morbidity through disability weights. Widely used in tuberculosis cost-effectiveness analysis (CEAs), DALYs play a significant role in informing intervention adopt/reject decisions. This study reviews the values and consistency of disability weights applied in tuberculosis-related CEAs.

Methods: We conducted a systematic review using the Tufts CEA database, updated to July 2023 with searches in Embase, Scopus and PubMed. Eligible studies needed to have included a cost-per-DALY ratio, and additionally either evaluated a tuberculosis (TB) intervention or included tuberculosis-related weights. We considered all tuberculosis health states: with/without human immunodeficiency virus (HIV) coinfection, TB treatments and treatment side effects. Data were screened and extracted independently by combinations of two authors.

Findings: A total of 105 studies spanning 2002-2023 across 50 countries (mainly low- and middle-income countries) were extracted. Disability weights were sourced primarily from the Global Burden of Disease (GBD; 100/165; 61%), with 17 non-GBD studies additionally referenced, along with primary derivation. Inconsistencies in the utilisation of weights were evident: of the 100 usages of GBD-sourced weights, only in 47 instances (47%) had the weight value been explicitly specified with an appropriate up-to-date reference cited (constituting 28% of all weight usages, 47/165). Sensitivity analyses on weight values had been conducted in 30% of studies (31/105). Twelve studies did not clearly specify weights or their sources; nine further calculated DALYs without morbidity. The review suggests methodological gaps in current approaches for representing important aspects of TB, including TB-HIV coinfection, treatment, drug-resistance, extrapulmonary TB and psychological impacts. We propose a set of best practice recommendations.

Interpretation: There is a need for increased rigour in the application, sensitivity testing and reporting of TB disability weights. Furthermore, there appears a desire among researchers to reflect elements of the tuberculosis experience beyond those allowed for by GBD disability weights.

References

Johnson K, Churchyard G, Sohn H, Dowdy D . Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. Clin Infect Dis. 2018; 67(7):1072-1078. DOI: 10.1093/cid/ciy230. View

Goodchild M, Sahu S, Wares F, Dewan P, Shukla R, Chauhan L . A cost-benefit analysis of scaling up tuberculosis control in India. Int J Tuberc Lung Dis. 2011; 15(3):358-62. View

Nsengiyumva N, Campbell J, Oxlade O, Vesga J, Lienhardt C, Trajman A . Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness. PLoS Med. 2022; 19(6):e1004032. PMC: 9239450. DOI: 10.1371/journal.pmed.1004032. View

Alene K, Wangdi K, Colquhoun S, Chani K, Islam T, Rahevar K . Tuberculosis related disability: a systematic review and meta-analysis. BMC Med. 2021; 19(1):203. PMC: 8426113. DOI: 10.1186/s12916-021-02063-9. View

Fekadu G, Wang Y, You J . Standard diagnostics with and without urine-based lipoarabinomannan testing for tuberculosis disease in HIV-infected patients in a high-burden setting-A cost-effectiveness analysis. PLoS One. 2023; 18(7):e0288605. PMC: 10348570. DOI: 10.1371/journal.pone.0288605. View

Tsevat J, Taylor W, Wong J, Pauker S . Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis. 1988; 137(1):215-20. DOI: 10.1164/ajrccm/137.1.215. View

Bauer M, Leavens A, Schwartzman K . A systematic review and meta-analysis of the impact of tuberculosis on health-related quality of life. Qual Life Res. 2012; 22(8):2213-35. PMC: 3825536. DOI: 10.1007/s11136-012-0329-x. View

Mohan C, Bishai D, Cavalcante S, Chaisson R . The cost-effectiveness of DOTS in urban Brazil. Int J Tuberc Lung Dis. 2007; 11(1):27-32. View

Jayawardana S, Weerasuriya C, Pelzer P, Seeley J, Harris R, Tameris M . Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis. NPJ Vaccines. 2022; 7(1):138. PMC: 9640704. DOI: 10.1038/s41541-022-00554-1. View

10.

Knight G, Griffiths U, Sumner T, Laurence Y, Gheorghe A, Vassall A . Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci U S A. 2014; 111(43):15520-5. PMC: 4217399. DOI: 10.1073/pnas.1404386111. View

11.

Salomon J, Vos T, Hogan D, Gagnon M, Naghavi M, Mokdad A . Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2129-43. PMC: 10782811. DOI: 10.1016/S0140-6736(12)61680-8. View

12.

Hunchangsith P, Barendregt J, Vos T, Bertram M . Cost-effectiveness of various tuberculosis control strategies in Thailand. Value Health. 2012; 15(1 Suppl):S50-5. DOI: 10.1016/j.jval.2011.11.006. View

13.

Bhargava A, Bhargava M, Meher A, Benedetti A, Velayutham B, Teja G . Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial. Lancet. 2023; 402(10402):627-640. DOI: 10.1016/S0140-6736(23)01231-X. View

14.

Shah M, Miele K, Choi H, DiPietro D, Martins-Evora M, Marsiglia V . QuantiFERON-TB gold in-tube implementation for latent tuberculosis diagnosis in a public health clinic: a cost-effectiveness analysis. BMC Infect Dis. 2012; 12:360. PMC: 3546858. DOI: 10.1186/1471-2334-12-360. View

15.

Usemann J, Ledergerber M, Fink G, Ritz N . Cost-effectiveness of tuberculosis screening for migrant children in a low-incidence country. Int J Tuberc Lung Dis. 2019; 23(5):579-586. DOI: 10.5588/ijtld.18.0356. View

16.

Dowdy D, OBrien M, Bishai D . Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis. 2008; 12(9):1021-9. View

17.

Wolfson L, Walker A, Hettle R, Lu X, Kambili C, Murungi A . Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. PLoS One. 2015; 10(3):e0120763. PMC: 4368676. DOI: 10.1371/journal.pone.0120763. View

18.

Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E . Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Appl Health Econ Health Policy. 2017; 16(1):43-54. DOI: 10.1007/s40258-017-0352-8. View

19.

Salomon J, Haagsma J, Davis A, Maertens de Noordhout C, Polinder S, Havelaar A . Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015; 3(11):e712-23. DOI: 10.1016/S2214-109X(15)00069-8. View

20.

Suarez P, Floyd K, Portocarrero J, Alarcon E, Rapiti E, Ramos G . Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet. 2002; 359(9322):1980-9. DOI: 10.1016/S0140-6736(02)08830-X. View